UroGen Pharma (URGN) Change in Acquisitions & Divestments (2018 - 2026)

UroGen Pharma (URGN) has reported Change in Acquisitions & Divestments for 9 consecutive years, with $4.1 million the latest figure, recorded in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 89.75% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $103.0 million (down 23.52% YoY) and the FY2025 annual result came in at $139.2 million, up 29.29% from the prior year.
• Change in Acquisitions & Divestments fell to $4.1 million in Q1 2026 per URGN's latest filing, from $28.3 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for URGN reached as high as $70.0 million in Q4 2024 and fell as low as -$88000.0 in Q2 2022.
• A 5-year average of $21.4 million and a median of $13.6 million in 2022 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments sank 100.8% — and 2023, when it jumped 4344.32%.
• Year by year, Change in Acquisitions & Divestments stood at $23.1 million in 2022, then sank by 84.71% to $3.5 million in 2023, then jumped by 1879.21% to $70.0 million in 2024, then sank by 59.59% to $28.3 million in 2025, then plunged by 85.34% to $4.1 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $4.1 million, $28.3 million, and $40.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.